Trial Profile
A Multicenter Randomized Double-blind Clinical Study Evaluated the Safety, Pharmacokinetic and Pharmacodynamic Characteristics of Roflumilast in COPD Patients
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 22 May 2019
Price :
$35
*
At a glance
- Drugs Roflumilast (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacokinetics
- Sponsors Chia Tai Tianqing Pharmaceutical Group
- 20 May 2019 Status changed from recruiting to discontinued.
- 23 Dec 2017 Planned End Date changed from 1 Aug 2017 to 1 Dec 2017.
- 23 Dec 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Dec 2017.